_______________________________________________________________

_______________________________________________________________

Report Information from ProQuest

03 October 2015 06:59
_______________________________________________________________

03 October 2015

ProQuest

Table of contents
1. Vermillion, Inc.; American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing
Positive Performance of Vermillion's OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer...

03 October 2015

ii

ProQuest

Document 1 of 1

Vermillion, Inc.; American Journal of Obstetrics &Gynecology Publishes New Clinical Study Showing
Positive Performance of Vermillion's OVA1 Test in Presurgical Detection of Early-Stage Ovarian
Cancer
ProQuest document link
Abstract (Abstract): "Our new study demonstrates OVA1's ability to detect the majority of all early-stage ovarian
cancers prior to surgery and thereby aid in appropriately involving a gynecologic oncologist in their care. Even
among premenopausal patients where primary ovarian cancer prevalence was only 15%, clinical assessment
with OVA1 detected early-stage ovarian cancer with nearly 90% sensitivity. This is a very encouraging
development for diagnosis and treatment of ovarian cancer."
Full text: 2013 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Oncology Business Week -- A new
study of OVA1(R) clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical
Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has been published in
The American Journal of Obstetrics &Gynecology.
Led by Dr. Robert E. Bristow (UC Irvine Healthcare) and Dr. Frederick R. Ueland (U. Kentucky), the new
analysis focuses on presurgical detection of early-stage ovarian cancer among 1,016 ovarian mass surgery
patients in two previous pivotal trials conducted in 2007 and 2012.
The study compared OVA1 performance in early-stage ovarian cancer to commonly used cancer risk
assessment protocols: overall clinical assessment, the CA125 biomarker or modified-American College of
Obstetricians and Gynecologists (mod-ACOG) guidelines for evaluation of suspicious pelvic masses. Vermillion,
Inc. (NASDAQ: VRML), the multivariate diagnostics company which developed and currently markets the test,
reported the findings today at the American Association of Gynecologic Laparoscopists "42(nd) AAGL Global
Congress on Minimally Invasive Gynecology."
"Early-stage ovarian cancer constitutes an important opportunity to improve survival and care for this most
deadly gynecologic cancer," said Dr. Bristow. "However, as evidenced by recent studies, most ovarian cancer
patients fail to be referred to the doctors and hospitals best equipped to treat them, resulting in unfortunate
consequences.
"Our new study demonstrates OVA1's ability to detect the majority of all early-stage ovarian cancers prior to
surgery and thereby aid in appropriately involving a gynecologic oncologist in their care. Even among
premenopausal patients where primary ovarian cancer prevalence was only 15%, clinical assessment with
OVA1 detected early-stage ovarian cancer with nearly 90% sensitivity. This is a very encouraging development
for diagnosis and treatment of ovarian cancer."
Keywords for this news article include: Cancer, Surgery, Oncology, Vermillion Inc.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013,
NewsRx LLC
People: Bristow, Robert E
Publication title: Oncology Business Week
First page: 194
Publication year: 2013
Publication date: Dec 1, 2013
Year: 2013

03 October 2015

Page 1 of 2

ProQuest

Publisher: NewsRx
Place of publication: Atlanta
Country of publication: United States
Publication subject: Business And Economics, Medical Sciences
ISSN: 15525635
Source type: Trade Journals
Language of publication: English
Document type: Expanded Reporting
ProQuest document ID: 1460175040
Document URL: http://search.proquest.com/docview/1460175040?accountid=25704
Copyright: Copyright 2013, Oncology Business Week via NewsRx.com
Last updated: 2013-11-21
Database: ProQuest Health Management

_______________________________________________________________
Contact ProQuest

Copyright 2015 ProQuest LLC. All rights reserved. - Terms and Conditions

03 October 2015

Page 2 of 2

ProQuest